TNT session

2018 euro PCR

"Amphilimus™ Eluting Stent: leveraging on innovative technology to go beyond current PCI clinical boundaries in diabetic and HBR patients"

Session objectives

Stefan Verheye
Antwerp Cardiovascular Center
ZNA Middelheim, Antwerp - Belgium

EAPCI European Society of Cardiology PCR

Speaker's name: **Stefan Verheye**

☑ I have the following potential conflicts of interest to report:

Receipt of honoraria or consultancy fees: Alvimedica; Biotronik; Neovasc

Agenda

12:15 - 12:17	Session Objectives	*S. Verheye*
12:17 - 12:25	Rethinking DES technology to advance device efficacy and safety	*R. Byrne*
12:25 - 12:33	Amphilimus eluting stent - clinical results and ongoing clinical plan	*R. Romaguera*
12:33 – 12:35	Patient presentation	*S. Verheye*
12:35 – 12:37	Key objectives, strategy, tools and technique presented by operators	
12:37 - 13:17	**40 mn - LIVE demonstration from Clinique Pasteur - Toulouse, France**	
13:17 - 13:27	Time to React@PCR	
13:27 - 13:35	PCI efficacy vs. bleeding - an interconnected equation	*P. Stella*
13:35 – 14:03	ReCre8 study – Recorded cases from University hospital Utrecht – Utrecht, Netherlands	*L. Timmers*
14:03 - 14:13	Time to React@PCR	
14:13 - 14:15	Session evaluation and key learnings	*R. Mehran*

Scientific Panel

- Chairperson: R. Mehran
- Co-chairperson: S. Verheye
- Speakers: R. Byrne, R. Romaguera, P. Stella, L. Timmers

- LIVE CASE operators at Clinique Pasteur:
  - B. Farah
  - D. Tchétché

Diabetes Mellitus & PCI

The number of DM pts is quickly growing



IDF DIABETES ATLAS
Eighth edition 2017



DES performance in DM pts is still unsatisfactory



Circulation. 2011;124:893-900.

HBR patients & PCI

Today many patients undergoing PCI are very complex, present several comorbidities and are in “fragile” conditions. These patients would benefit from a reduced DAPT duration as their risk of bleeding is very high.

Examples:

- Patients > 75years
- Patients with OAC
- Patients with prior stroke
- Patients with bleeding disorder
- Patients with cancer
- Patients needing an urgent surgical intervention
- . . .



Background - II

Cre8™ EVO embeds a totally new DES technology vs. the standard one on the market. Its controlled polymer-free Amphilimus™ elution from Abluminal Reservoirs is empowered by an innovative stent architecture (EvenArt). These unique and innovative features may enhance clinical outcomes in complex patients, such as those with diabetes mellitus and at HBR, improving their clinical outcome.